INDICATIONS
Photrexa
®
Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) and Photrexa
®
(riboflavin
5'-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-
linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.
Corneal collagen cross-linking should not be performed on pregnant women.
IMPORTANT SAFETY INFORMATION
Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects.
The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include
punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced
visual acuity, and blurred vision.
These are not all of the side effects of the corneal collagen cross-linking treatment. For more information,
go to www.livingwithkeratoconus.com to obtain the FDA-approved product labeling.
You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.
*
Photrexa
®
Viscous and Photrexa
®
are manufactured for Avedro. The KXL System is manufactured by Avedro.
Avedro is a wholly owned subsidiary of Glaukos Corporation.
REFERENCE: 1. Photrexa [package insert] Waltham, MA: Glaukos, Inc. 2016.
MA-01953A
© 2020 Glaukos Corporation. iLink
™
is a trademark of Glaukos Corporation. Glaukos and Photrexa
®
are registered trademarks of Glaukos Corporation.
Using Photrexa
®
Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic
solution), Photrexa
®
(riboflavin 5'-phosphate ophthalmic solution) and the
KXL
®
system, the iLink corneal cross-linking procedure from Glaukos is the
only FDA-approved therapeutic treatment for patients with progressive
keratoconus and corneal ectasia following refractive surgery.*
1
Now from GLAUKOS
LEARN MORE AT GLAUKOS.COM
GET THERE IN TIME
iLink
™
is the only FDA-approved cross-linking
procedure that slows or halts progressive
keratoconus to help you preserve vision.
